hotspot -WSS

hotspot

author：comprehensive 2025-10-01 02:15:49 - browse：91

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Senators push IRS to launch nonprofit hospital probe

WSS

David Sabatini, ex

Heat waves linked to early deliveries, preterm births in new study

Schizophrenia gene found to be linked to cells' energy dysfunction

Idaho college killings prosecutors challenge defense's grand jury claims

Antibiotic resistance nearly killed me, so I'm raising awareness of it

iTeos Therapeutics debuts first data on TIGIT

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

The cancer drug shortage isn’t new — and neither are the solutions

Novo Nordisk touts Wegovy study, but still struggling with supply

Medical leaders decry Supreme Court decision on affirmative action

Illumina slashes 2023 revenue projections yet again

Peter Hotez and the public health issue of online harassment

Childbirth

In age of alternative facts, a scholarly course on calling out crap

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

hotspot

Timeline: How the deadly wildfires took over Maui day by day

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

What to know about the judge who will handle the Trump case

YouTube cracks down on misinformation on cancer treatment

Addiction doctors spar with methadone clinics over legislation

knowledge

hotspot

focus

hotspot